Koefisien utang jangka dawa marang modal Greenwich LifeSciences Inc (GLSI)

The market trend for Greenwich LifeSciences (GLSI), whose business focuses on combating breast cancer, is currently at 0.00. The firm's prospects are tied to the results of final vaccine tests, while existing reserves are sufficient to complete R&D. The GP2 product will provide the company with pricing power due to the absence of patient relapses. Decisive management is focused on the drug's success and is collaborating closely with physicians.

This ratio compares the volume of liabilities with a maturity of more than one year to the amount of equity, determining the degree of financial leverage and the stability of the balance sheet structure. For the biopharmaceutical business of Greenwich LifeSciences (GLSI), which is establishing a protected patent perimeter in immuno-oncology, the history of long-term debt-to-equity demonstrates a balance between investments in GP2 vaccine development and the risk of excessive credit dependence.